These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28623068)

  • 1. Corrigendum to "Comparative study of therapeutic response to baclofen vs tolperisone in spasticity" [Biomed. Pharmacother. 87 (2017) 628-635].
    Agarwal S; Patel T; Shah N; Patel BM
    Biomed Pharmacother; 2017 Aug; 92():1140. PubMed ID: 28623068
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative study of therapeutic response to baclofen vs tolperisone in spasticity.
    Agarwal S; Patel T; Shah N; Patel BM
    Biomed Pharmacother; 2017 Mar; 87():628-635. PubMed ID: 28086137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum to "Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review" [Biomed. Pharmacother. 92 (2017) 681-689].
    Anjum K; Shagufta BI; Abbas SQ; Patel S; Khan I; Shah SAA; Akhter N; Shams-Ul-Hassan S
    Biomed Pharmacother; 2018 May; 101():820. PubMed ID: 29525678
    [No Abstract]   [Full Text] [Related]  

  • 4. Retraction notice to "The comparative study of clinical efficacy and safety of baclofen vs tolperisone in spasticity caused by spinal cord injury" [Saudi Pharm. J. 25 (2017) 655-659].
    Luo D; Wu G; Ji Y; Zhang Z; He F; Mou X; Zhu Q; Yang B
    Saudi Pharm J; 2020 May; 28(5):639. PubMed ID: 32435148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A randomized, double blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke].
    Stamenova P; Koytchev R; Kuhn K; Hanasen C; Horvath F; Ramm S; Pongratz D
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(1):34-42. PubMed ID: 16457132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke.
    Stamenova P; Koytchev R; Kuhn K; Hansen C; Horvath F; Ramm S; Pongratz D
    Eur J Neurol; 2005 Jun; 12(6):453-61. PubMed ID: 15885050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retraction notice to "Corrigendum to 'mPEG-b-P(Glu-co-Phe) nanoparticles increase gastric retention time and gastric ulcer treatment efficacy of 20(S)-ginsenoside Rg3' [Biomed. Pharmacother. 146 (2022) 112608]" [Biomed. Pharmacother. 152 (2022) 113213].
    Cao L; Wang S; Zhang L; Li J
    Biomed Pharmacother; 2023 Apr; 160():114280. PubMed ID: 36725470
    [No Abstract]   [Full Text] [Related]  

  • 8. Corrigendum to "double sword role of EZH2 in leukemia" [Biomed. Pharmacother. 98 (2018) 626-635].
    Safaei S; Baradaran B; Hagh MF; Alivand MR; Talebi M; Gharibi T; Solali S
    Biomed Pharmacother; 2018 May; 101():786. PubMed ID: 29525673
    [No Abstract]   [Full Text] [Related]  

  • 9. Corrigendum to "Study on the efficacy and mechanism of triptolide on treating TNF transgenic mice with rheumatoid arthritis" [Biomed. Pharmacother. 106 (2018) 813-820].
    Wang S; Zuo S; Liu Z; Ji X; Yao Z; Wang X
    Biomed Pharmacother; 2019 Mar; 111():1509. PubMed ID: 30413297
    [No Abstract]   [Full Text] [Related]  

  • 10. Corrigendum to "Dexmedetomidine relieves formaldehyde-induced pain in rats through both α2 adrenoceptor and imidazoline receptor" [Biomed. Pharmacother. 90 (2017) 914-920].
    Zhang H; Yan X; Wang DG; Leng YF; Wan ZH; Liu YQ; Zhang Y
    Biomed Pharmacother; 2017 Dec; 96():1569. PubMed ID: 29153378
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to "Carnitine/organic cation transporter 2 (OCTN2) contributes to rat epididymal epithelial cell growth and proliferation" [Biomed. Pharmacother. 93(2017):444-450].
    Li D; Liu J; Wei D; Liu H; Xiao W; Song X; Fan Z; Ke C; Qiangguo Y; Qin W; Tang Y; Xiaoyong P
    Biomed Pharmacother; 2018 Aug; 104():854. PubMed ID: 29753602
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "miR-142-5p promotes development of colorectal cancer through targeting SDHB and facilitating generation of aerobic glycolysis" [Biomed. Pharmacother. 92 (2017) 1119-1127].
    Liu S; Xiao Z; Ai F; Liu F; Chen X; Cao K; Ren W; Zhang X; Shu P; Zhang D
    Biomed Pharmacother; 2018 Mar; 99():1033-1036. PubMed ID: 29398246
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to "Luteolin, a flavonoid, as an anticancer agent: A review" [Biomed. Pharmacother. 112 (2019) 108612].
    Imran M; Rauf A; Abu-Izneid T; Nadeem M; Shariati MA; Khan IA; Imran A; Erdogan Orhan I; Rizwan M; Atif M; Aslam Gondal T; Mubarak MS
    Biomed Pharmacother; 2019 Aug; 116():109084. PubMed ID: 31178263
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to "Incretin hormones receptor signaling plays the key role in antidiabetic potential of PTY-2 against STZ-induced pancreatitis" [Biomed. Pharmacother. 97 (330-338) 330-338].
    Srivastava S; Shree P; Pandey H; Tripathi YB
    Biomed Pharmacother; 2018 Nov; 107():1795. PubMed ID: 30115498
    [No Abstract]   [Full Text] [Related]  

  • 15. Corrigendum to "MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC" [Biomed. Pharmacother. 110 (2019) 656-666].
    Quan J; Pan X; Li Y; Hu Y; Tao L; Li Z; Zhao L; Wang J; Li H; Lai Y; Zhou L; Lin C; Gui Y; Ye J; Zhang F; Lai Y
    Biomed Pharmacother; 2019 Apr; 112():108755. PubMed ID: 30871752
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacological studies of 1-(2,3-dimethyl-4-methoxyphenyl)-2-methyl-3-(1-pyrrolidinyl)-1- propanone hydrochloride (AD-2239), a centrally acting muscle relaxant.
    Ito T; Hori M; Furukawa K; Karasawa T; Kadokawa T
    Arch Int Pharmacodyn Ther; 1985 May; 275(1):105-22. PubMed ID: 3839647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corrigendum to "LINC00657 played oncogenic roles in esophageal squamous cell carcinoma by targeting miR-615-3p and JunB" [Biomed. Pharmacother. 108 (2018) 316-324].
    Yuchen S; Jizhao W; Shupei P; Tian Y; Xuanzi S; Ya W; Xiaobo S; Xu Z; Jing G; Xiaozhi Z
    Biomed Pharmacother; 2019 Mar; 111():1507. PubMed ID: 30600121
    [No Abstract]   [Full Text] [Related]  

  • 18. Corrigendum to "Herb-drug interaction: A case study of effects and involved mechanisms of cisplatin on the pharmacokinetics of ginsenoside Rb1 in tumor-bearing mice" [Biomed. Pharmacother. 110 (2019) 95-104].
    Zhou J; Wu J; Wu CY; Long F; Shen H; Zhang W; Li SL
    Biomed Pharmacother; 2019 Jun; 114():108827. PubMed ID: 30954310
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "Noscapinoids bearing silver nanocrystals augmented drug delivery, cytotoxicity, apoptosis and cellular uptake in B16F1, mouse melanoma skin cancer cells" [Biomed. Pharmacother. 90 (2017) 906-913].
    Soni N; Jyoti K; Jain UK; Katyal A; Chandra R; Madan J
    Biomed Pharmacother; 2018 Sep; 105():1360. PubMed ID: 29929878
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "Cerebral dopamine neurotrophic factor protects microglia by combining with AKT and by regulating FoxO1/mTOR signaling during neuroinflammation" [Biomed. Pharmacother. 109 (2018) 2278-2284].
    Zhang Y; Xiang Y; Wang X; Zhu L; Li H; Wang S; Pan X; Zhao H
    Biomed Pharmacother; 2019 Apr; 112():108548. PubMed ID: 30773235
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.